Ticagrelor
Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
Product Specifications
CAS Number
274693-27-5
Product Name Alternative
AZD6140; AR-C 126532XX
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
P2Y Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Ticagrelor.html
Purity
99.98
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
P2Y12 Receptor
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470630-100 1x 100 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400824-100 1x 100 µL
CD68 (LAMP4/824), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details